Newsletter | July 18, 2025

07.18.25 -- Why CDMOs Are Leaving Small Molecules Behind

INDUSTRY INSIGHTS

Head Pressure In Your Hopper: What Is It, And How Do You Mitigate It?

Examine how head pressure influences formulation flow, impacts tablet press performance, and why mastering flow dynamics is critical to ensuring consistent tablet quality.
 

Digital Transformation In Contract Manufacturing: A Leadership Perspective

Gain expert insight on overcoming challenges, driving innovation, and maintaining core values in a regulated industry.

Engineering Approaches To Respiratory Drug Delivery

Explore the material and performance properties of spray-dried and jet-milled mannitol for respiratory delivery of crystalline mannitol.

FEATURED EDITORIAL

Why CDMOs Are Leaving Small Molecules Behind

It’s rare when a CDMO’s restructuring leads to thoughts about national health policy. But as Chief Editor Louis Garguilo wrote his recent editorial on Lonza’s decision to focus heavily on biologics, it brought to mind a government policy that may have contributed to the company’s restructuring. No, it's not tariffs.

Are You Asking For Unrealistic Flexibility At Your CDMO?

Our experienced Outsourced Pharma Live panel considers what is doable, and what is not, when it comes to the demands some sponsors put on CDMOs.

INDUSTRY INSIGHTS CONTINUED

Partnership Goals For Scale-Up Success

As demand for capabilities and resources grows throughout a project, both become strained, and the scale-up process becomes a steeper hill to climb.

Highly Potent API Drug Product Development Using Micronization Technology

Consider how the need for reliable manufacturing technologies has become critical, making it essential to partner with an experienced HPAPI manufacturer for safe product development.

Fixtures And Surrogates For Combination Product Performance Testing

The combination product market is consistently expanding. Transitioning from traditional vial systems to needle-based products presents several challenges that require careful consideration.

SOLUTIONS

Primary Drug Containers

Offering a wide range of benefits over traditional glass-based systems the use of cyclic olefin copolymer (COC) allows for much greater design flexibility, and the creation of more robust containers.

Sterile Drug Product Expansion

Discover our network's regulatory starting material capabilities and an innovative business model that does not add additional costs to your project.

Comprehensive Regulatory Support

Review our expertise across a wide range of global markets, and how securing regulatory approvals and navigating market challenges positions us as a trusted partner.

OUTSOURCED PHARMA CAPACITY UPDATE

Find Your New CDMO At Outsourced Pharma Capacity Update

CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capacities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.

Connect With Outsourced Pharma: